< Terug naar vorige pagina


G Vanham

  • Gebruikers van onderzoeksexpertise:

    Guido Vanham graduated as a medical doctor in 1980 and as a specialist in internal medicine in 1987. During the eighties he performed research at the labs of Immunology and Endocrinology of the Catholic University of Leuven.

    In 1989 he joined the Laboratory of Immunology of ITM and prepared a PhD thesis on immune activation and anergy in HIV, which was defended in 1994. Based on this early work, he performed various immunological studies on HIV and tuberculosis in joint projects with Case Western Reserve University (CRWU) in Cleveland, OH and the Mulago Hospital in Kampala, Uganda.

    From the end of the nineties on, Guido Vanham focused on the interaction between HIV, dendritic cells and T cells.  From that fundamental interest emerged two lines of translational research: search for microbicides (HIV preventive drugs) and dendritic-cell based immunotherapy.  In collaboration with CWRU question related to determinants of HIV replication capacity (fitness) were addressed.  Moreover, multidisciplinary studies on a large cohort of HTLV-1 infected subjects in Lima, Peru were also initiated.

    Since 2004, Guido Vanham is the head of the Virology Unit, where he continues working on HIV microbicides, immunotherapy and fitness, as well as on HTLV-1 in Peru. The work of his predecessor on neutralizing antibodies as a basis for HIV vaccine development is being expanded.  In addition, some studies on HIV-2 are being carried out in collaboration with MRC, the Gambia.

    At present, the Virology Unit, has three postdoctoral fellows, one molecular engineer, six PhD students, seven lab technicians and two secretarial/administrative people (shared with other units).

    Guido Vanham is also a member of the Institutional Review Board of ITM, professor in Tropical Infectious Diseases at the University of Antwerp (UA) and visiting professor in Cell and Gene Therapy at the Free University of Brussels (VUB).   He serves in scientific committees of the Flemish Institute of Science and Technology (IWT), the French Agence Nationale de Recherche sur le SIDA (ANRS) and the US National Institutes of Health (NIH).

    Research lines
    • HIV vaccine through analysis of neutralizing antibodies
    • HIV microbices against reverse transcriptase and integrase
    • HIV immunotherapy: Gag mRNA transfection of dendritic cells
    • HTLV-1 in Peru: pathogenesis and epidemiology
    • HIV-2 drug resistance in West Africa